drugset / Trial / NCT01670773

A Study of CAT-1004 Biomarkers in Healthy Subjects

NCT01670773 ↗

Phase 1 Completed 9 enrolled Catabasis Pharmaceuticals
RandomizedCrossoverSingle-blindBasic science

Summary

This study is being conducted to assess mechanistic blood biomarkers of CAT-1004 in healthy humans.

Timeline

Start
2012-08
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator DHA Unknown — —
Subject Edasalonexent Small molecule — —
Comparator Salsalate Small molecule — —

Indications

No indication recorded.